Cette page contient les dernières mises à jour et actualités de BianchiSchwald, allant de coupures d’articles de presse aux publications de nos avocats, en passant par les nouveautés juridiques. Si vous voulez en savoir plus, veuillez nous contacter directement
BianchiSchwald’s Junior Associate Maxence Carron has recently coauthored a case law review on Swiss road traffic law. This contribution was published in the leading Journal des Tribunaux in Lausanne.
Gianni Fera was member of the college of Walter Andreoni, Partner at Mercanti Dorio e Associati, to discuss and exchange on taxation of Real Estate investments in selected countries. The presentation was focused on taxation of real estate investissment in Italy, United Arab Emirats, the U.S.A., Switzerland and in Russia. Gianni Fera presented the taxation of real-estate investments in Switzerland.
Partner Yves de Coulon has been interviewed by the real estate Geneva newspapers Tout l’Immobilier about the Lake Geneva Region stand at the MIPIM.
Yves de Coulon is chairman of the association which organises and operates the LGR stand.
Within the AGEFI’s monthly Supplément Indices, Thomas Goossens and Stéphanie Chuffart-Finsterwald provide clarifications on the current status of initial coin offerings (ICOs) in Switzerland with regard to the new ICO guidelines published by the FINMA on 18 February 2018.
The 2018 edition of Chambers Europe distinguishes 9 partners as leaders in their field and recognizes BianchiSchwald in 5 practice areas: Corporate/M&A, Employment, Real estate, Banking & finance, and Intellectual property. It is to be noted that our Corporate/M&A, as well as our Employment practice groups both improved their ranking in this edition (respectively tiers 4 and tiers 3), and so did Stéphanie Fuld (tiers 2). These results are representative of BianchiSchwald’s constant effort to provide its clients the best possible advice.
BianchiSchwald – team led by Thomas Goossens, Joseph Merhai and Stéphanie Chuffart-Finsterwald – is proud to have assisted the company and its founders in the context of the up to EUR 1 billion acquisition of Prexton Theurapeutics by the Danish pharma Lundbeck. Prexton Theurapeutics is a biopharmaceutical company founded in 2012 applying a new scientific approach for the treatment of Parkinson’s disease and other brain disorders.